|
시장보고서
상품코드
2091223
우르소데옥시콜산 시장 규모, 점유율, 성장 분석 : 적응증별, 제형별, 유통 경로별, 최종사용자별, 제품별, 지역별 - 업계 예측(2026-2033년)Ursodeoxycholic Acid Market Size, Share, and Growth Analysis, By Indication (Primary Biliary Cholangitis (PBC), Gallstone Dissolution), By Formulation (Capsules, Tablets), By Distribution, By End-User, By Product, By Region - Industry Forecast 2026-2033 |
||||||
세계의 우르소데옥시콜산 시장 규모는 2024년에 7억 514만 달러로 평가되었으며, 2025년 7억 7,636만 달러에서 2033년까지 16억 7,633만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 10.1%로 성장할 것으로 전망됩니다.
우르소데옥시콜산(UDCA) 시장은 특히 비알코올성 지방간염(NASH) 및 신경퇴행성 질환 분야의 적응증 확장에 힘입어 크게 성장하고 있습니다. 현재 진행 중인 임상시험에서는 UDCA가 염증 경로를 효과적으로 조절하고 미토콘드리아 기능을 향상시킨다는 사실이 시사되고 있으며, 각 제약사는 UDCA와 항섬유화제를 결합한 혁신적인 병용요법에 대한 연구를 진행하고 있어, 이를 통해 새로운 수익 기회가 창출되고 있습니다. 이러한 추세에 따라 연구개발 투자가 증가하고 있으며, 특히 간 질환 사례가 급증하고 있는 신흥 경제국에서 규제 당국에 제출되는 신청 건수가 늘어나고 시장 진입이 확대되고 있습니다. 아시아 병원들의 UDCA 도입 현황은 전략적인 가격 책정 계약을 통해 조달 비용이 절감되고, 그 사용이 더욱 촉진되며, 시장 내의 큰 성장 잠재력이 이끌어지고 있음을 보여줍니다.
세계 우르소데옥시콜산 시장의 성장요인
세계 우르소데옥시콜산 시장은 원발성 담관염 및 담석 관련 질환 등 담즙 정체성 간 질환의 유병률 증가에 큰 영향을 받고 있습니다. 이러한 질환에 대해서는 담즙의 흐름을 개선하고 간 염증을 완화하는 효과적인 치료법이 요구되고 있습니다. 의료 종사자들이 이러한 질환에 대한 적시 치료의 중요성을 점점 더 인식함에 따라, 우르소데옥시콜산은 1차 치료법으로 권장되는 경우가 늘고 있습니다. 또한, 조기 개입을 권장하는 임상 지침의 지속적인 개정이 수요를 더욱 부추기고 있을 뿐만 아니라, 환자 지원 활동을 통해 이러한 질환에 대한 인식이 높아지면서 조기 진단과 다양한 의료 환경에서의 보다 일관된 처방 관행으로 이어지고 있습니다.
세계 우르소데옥시콜산 시장의 제약요인
세계 우르소데옥시콜산 시장은 주로 보건 당국이 의무화한 엄격한 안전성 및 유효성 기준으로 인해 큰 제약을 받고 있습니다. 이러한 요건들로 인해 심사 기간이 길어지면서, 신규 진입 기업의 시장 진입을 저해하고 있습니다. 임상시험 설계의 복잡성에 더해, 엄격한 문서화 프로토콜이 요구되기 때문에 개발 기간이 길어지고, 자원 투자도 늘어납니다. 이로 인해 소규모 제조업체들이 혁신적인 솔루션을 추구하는 데 주저할 가능성이 있습니다. 그 결과, 새로운 투여 시스템이나 개선된 제제의 도입이 저해되어, 변화하는 치료 수요에 신속하게 대응하는 시장의 능력이 제한되고 있습니다. 또한, 규제 측면의 불확실성이 잠재적 투자자들의 위험 인식이 높아지는 한 요인이 되고 있습니다.
세계 우르소데옥시콜산 시장의 동향
세계 우르소데옥시콜산 시장에서는 정밀 의학의 도입을 향한 뚜렷한 추세가 나타나고 있습니다. 첨단 유전자 및 표현형 프로파일링의 통합을 통해 담즙 정체성 간 질환의 치료 전략이 변화하고 있습니다. 바이오마커에 기반한 알고리즘을 활용함으로써, 임상의는 개별 환자에게 맞춤형 치료를 시행할 수 있게 되어 치료 성과를 향상시킬 뿐만 아니라, 시행착오를 거치는 처방으로 인한 비효율성을 최소화할 수 있습니다. 이러한 맞춤형 접근 방식은 효과성을 높일 뿐만 아니라 가격 결정력을 강화하고, 제약사와 진단기기 제조사 간의 제휴를 촉진하고 있습니다. 이러한 제휴는 제품의 차별화를 촉진하며, 전 세계의 전문 의료 센터 및 대학병원에서 시장 확대를 위한 새로운 기회를 창출하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 우르소데옥시콜산 시장 규모 : 적응증별
세계의 우르소데옥시콜산 시장 규모 : 제제별
세계의 우르소데옥시콜산 시장 규모 : 유통별
세계의 우르소데옥시콜산 시장 규모 : 최종사용자별
세계의 우르소데옥시콜산 시장 규모 : 제품별
세계의 우르소데옥시콜산 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Ursodeoxycholic Acid Market size was valued at USD 705.14 Million in 2024 and is poised to grow from USD 776.36 Million in 2025 to USD 1676.33 Million by 2033, growing at a CAGR of 10.1% during the forecast period (2026-2033).
The market for Ursodeoxycholic Acid (UDCA) is significantly driven by its expanding indications, particularly in the realms of non-alcoholic steatohepatitis (NASH) and neurodegenerative disorders. Ongoing clinical trials suggest that UDCA effectively modulates inflammatory pathways and enhances mitochondrial function, prompting pharmaceutical companies to explore innovative combination therapies that integrate UDCA with antifibrotic agents, thereby generating new revenue opportunities. This dynamic fosters increased investment in research and development, leading to a rise in regulatory submissions and broader market accessibility, especially in emerging economies experiencing a surge in liver disease cases. The adoption of UDCA in Asian hospitals demonstrates how strategic pricing agreements have reduced acquisition costs, further encouraging its utilization and unlocking significant growth potential within the market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ursodeoxycholic Acid market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ursodeoxycholic Acid Market Segments Analysis
Global ursodeoxycholic acid market is segmented by indication, formulation, distribution, end-user, product and region. Based on indication, the market is segmented into Primary Biliary Cholangitis (PBC), Gallstone Dissolution, Non-Alcoholic Fatty Liver Disease and Primary Sclerosing Cholangitis. Based on formulation, the market is segmented into Capsules and Tablets. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on end-user, the market is segmented into Hepatology Clinics and Hospitals. Based on product, the market is segmented into Branded (Ursofalk, Actigall) and Generics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ursodeoxycholic Acid Market
The global market for Ursodeoxycholic Acid is significantly influenced by the growing prevalence of cholestatic liver diseases, such as primary biliary cholangitis and gallstone-related conditions, which necessitate effective therapeutic solutions that enhance bile flow and alleviate hepatic inflammation. As healthcare providers increasingly recognize the importance of timely treatment for these conditions, Ursodeoxycholic Acid is often recommended as a primary therapeutic option. Additionally, the ongoing evolution of clinical guidelines promoting early intervention further fuels demand, while patient advocacy initiatives increase awareness around these diseases, leading to earlier diagnoses and more consistent prescribing practices across varying healthcare environments.
Restraints in the Global Ursodeoxycholic Acid Market
The Global Ursodeoxycholic Acid market faces significant constraints primarily due to stringent safety and efficacy standards mandated by health authorities. These requirements lead to prolonged review cycles that hinder the market entry of new players. The intricate nature of clinical trial designs, alongside demanding documentation protocols, extends development timelines and escalates resource investments, which may deter smaller manufacturers from pursuing innovative solutions. As a result, the introduction of novel delivery systems and enhanced formulations is impeded, restricting the market's capacity to swiftly adapt to evolving therapeutic demands. Additionally, regulatory uncertainties contribute to heightened risk perceptions among potential investors.
Market Trends of the Global Ursodeoxycholic Acid Market
The Global Ursodeoxycholic Acid market is experiencing a significant trend towards the adoption of precision medicine, where the integration of advanced genetic and phenotypic profiling is transforming treatment strategies for cholestatic liver disorders. By utilizing biomarker-guided algorithms, clinicians are able to tailor therapies to individual patients, leading to improved therapeutic outcomes and minimizing the inefficiencies of trial-and-error prescribing. This personalized approach not only enhances efficacy but also allows for stronger pricing power, fostering collaborations between pharmaceutical companies and diagnostics firms. Such partnerships are driving product differentiation and creating novel opportunities for market expansion across specialty and academic medical centers worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Ursodeoxycholic Acid Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Primary Biliary Cholangitis (PBC)
- Gallstone Dissolution
- Non-Alcoholic Fatty Liver Disease
- Primary Sclerosing Cholangitis
Global Ursodeoxycholic Acid Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Capsules
- Tablets
Global Ursodeoxycholic Acid Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online
Global Ursodeoxycholic Acid Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hepatology Clinics
- Hospitals
Global Ursodeoxycholic Acid Market Size by Product & CAGR (2026-2033)
- Market Overview
- Branded (Ursofalk)
- Actigall
- Generics
Global Ursodeoxycholic Acid Market Size & CAGR (2026-2033)
- North America (Indication, Formulation, Distribution, End-User, Product)
- US
- Canada
- Europe (Indication, Formulation, Distribution, End-User, Product)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Formulation, Distribution, End-User, Product)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Formulation, Distribution, End-User, Product)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Formulation, Distribution, End-User, Product)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Falk Pharma GmbH (Ursofalk)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ratiopharm (Teva)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Watson Pharmaceuticals (Allergan/AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Actavis (AbbVie/Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Falk Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daewoong Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lohmann Therapy Systems
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aptalis Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intercept Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Axcan Pharma (Aptalis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mitsubishi Tanabe Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
